Owkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement with AstraZeneca
Owkin official newsroom · Indexed industry source record · Source published: Wed May 13 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 09:08:37 GMT+0000 (Coordinated Universal Time)
Saved source excerpt
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to revolutionize drug discovery and development, today announced an agreement with AstraZeneca to build biopharma agents as part of their three-year licensing of K Pro – Owkin’s AI Scientist for biopharma decision making. K Pro brings multimodal data and specialized biological agentic AI to each step of the value chai
This is a cited excerpt from the source. Read the original link for the complete text. Automated indexing and topic classification do not constitute fact verification.